Vandana Singh
·
July 22, 2025
Benzinga
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
read more
September 19, 2025
September 5, 2025
July 4, 2025
Bloomberg
July 16, 2025
August 20, 2025
Barchart